Overcoming IPF and Other Rare Respiratory Disease Clinical Trial Challenges, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain an overview of idiopathic pulmonary fibrosis (IPF) and other rare respiratory diseases, including the current landscape. Attendees will gain insights into endpoint selection considerations, as well as novel technologies and advancements. The featured speakers will share trial design strategies to minimize participant burden and maximize enrollment in rare respiratory studies. Attendees will also learn about harnessing AI and advanced data analytics to enable real-time monitoring and decision-making, accelerate study timelines and enhance data integrity.

TORONTO, Sept. 3, 2025 /PRNewswire/ -- Patients diagnosed with idiopathic pulmonary fibrosis (IPF) and other rare respiratory diseases often face a poor prognosis and limited treatment options. Although the two approved IPF treatments slow disease progression, there are currently no treatments that reverse the disease or offer a cure. Similar challenges are seen across many other rare respiratory diseases. The complexities associated with diagnosing these rare diseases, understanding their root causes, and translating preclinical findings to clinical success make these challenging diseases for drug development. However, recent advancements and strategic approaches in clinical trials are offering hope to patients that additional treatments are forthcoming.

Biopharma and Biotech R&D is undergoing a transformative shift driven by data and AI. In clinical trials, RWD and AI-enabled trial design and execution promise faster development timelines, better quality, and higher probabilities of success. Over 100 AI/ML technologies have been submitted to the US FDA; with the anticipation that use of AI optimizes drug discovery, efficacy prediction, and repurposing of existing drugs. AI efforts are focused on key value areas that include designing smarter and more efficient trials, supporting the acceleration of patient recruitment and increasing retention and AI-enabled medical writing.

Register for this webinar to explore the changing landscape, recent advancements and proven strategic approaches to overcoming clinical trial challenges in rare respiratory disease research.

Join experts from the PPD clinical research business of Thermo Fisher Scientific, Francis Jones, PhD, Executive Director, Project Management; Terri Denissen, Senior Director, Trial Project Oversight; Alex Auais, MD, Executive Medical Director, Medical Science & Strategy; and Gino Pirri, Vice President, Head of Digital Products, for the live webinar on Friday, September 19, 2025, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Overcoming IPF and Other Rare Respiratory Disease Clinical Trial Challenges.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks